Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of sitagliptin versus glimepiride in type 2 diabetes inadequately controlled on metformin
2007-000145-35Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change in HbA1c at 30 weeks. Started Feb 2008; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-000145-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000145-35.